Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multi-continent clinical trial

Acyclovir suppressive therapy (400 mg twice daily) reduces herpes simplex virus type 2 (HSV-2) associated genital ulcer disease (GUD) and lesional HSV shedding. In an international trial of acyclovir for HSV-2 suppression to prevent HIV acquisition (HPTN 039), acyclovir had a smaller effect on the f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fuchs, Jonathan, Celum, Connie, Wang, Jing, Hughes, James, Sanchez, Jorge, Cowan, Frances, Reid, Stewart, Delany-Moretlwe, Sinead, Corey, Lawrence, Wald, Anna
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2856478/
https://ncbi.nlm.nih.gov/pubmed/20214474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/651381
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars